Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients

Launched by TANTA UNIVERSITY · Mar 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well a test called fecal calprotectin can predict the presence and severity of esophageal varices, which are enlarged veins in the esophagus that can occur in patients with liver cirrhosis. The researchers want to see if measuring fecal calprotectin is as effective as other non-invasive scoring methods for identifying these varices in Egyptian patients. To do this, they will compare the levels of fecal calprotectin in patients with cirrhosis who do or do not have esophageal varices, as well as in healthy individuals.

Eligible participants must be at least 18 years old and diagnosed with liver cirrhosis. Those who have certain conditions like inflammatory bowel disease, cancer, or who are taking specific medications will not be included. If you choose to participate, you can expect to undergo several assessments, including a medical history review, physical examination, laboratory tests, and imaging studies, as well as an endoscopy, which is a procedure that allows doctors to look at your esophagus. This study is currently recruiting participants, and your involvement could help improve how doctors predict and manage esophageal varices in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Liver cirrhosis
• Exclusion Criteria:
• • Patients aged \< 18 years.
• • Inflammatory bowel disease.
• • Infectious gastroenteritis.
• • Malignancy.
• • Patients on proton pump inhibitors or NSAID.
• • Patients with spontaneous bacterial peritonitis.
• • Patients with hepatic encephalopathy.
• • Unwilling to participate in our study.